secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncotelic Therapeutics, Inc. (OTLC)
CIK:        0000908259
Form:       8-K
Filed at:   2023-01-03T23:59:59+00:00
Accession:  0001493152-23-000046
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncotelic details 2023 pipeline: 10+ OT-101 trials, pancreatic & glioma FPI, BARDA award
--------------------------------------------------------------------------------

- At least 10 investigator-initiated OT-101 trials planned in 2023 for NSCLC, pancreatic, melanoma, gliomas.
- Phase 2/3 pancreatic cancer trial expected FPI 2023; 55% long-term disease control in prior P001 study.
- BARDA awarded maximum EZ-BAA funding for OT-101 long COVID; observational trial starts 2023.
- Subsidiary Pet2DAO to launch PDAO token and distribute to shareholders/stakeholders in 2023.
- R&D costs reduced >95%, G&A >50% per latest 10Q; new CMO and CRO added.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/908259/000149315223000046/0001493152-23-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/908259/000149315223000046/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer